Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10004931 | 0.84 | MAPK1 (0.35) | USP2SMN1; SMN2CYP4F2CYP4A11KMT2A | |
| SCHEMBL1700334 | 0.84 | USP2 (0.33) | USP2SMN1; SMN2CYP4F2CYP4A11POLB | |
| SCHEMBL15897368 | 0.83 | USP2 (0.31) | USP2SMN1; SMN2CYP4F2CYP4A11POLB | |
| SCHEMBL15722043 | 0.81 | USP2 (0.32) | USP2SMN1; SMN2CYP4F2CYP4A11POLB | |
| SCHEMBL22098152 | 0.79 | USP2 (0.43) | USP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL15867787 | 0.77 | DGAT1 (0.33) | USP2SMN1; SMN2POLBKMT2A | |
| SCHEMBL26410070 | 0.77 | MAPK1 (0.32) | CYP4F2CYP4A11 | |
| SCHEMBL20772092 | 0.77 | CYP4F2 (0.33) | USP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL26409859 | 0.76 | TSHR (0.31) | CYP4F2CYP4A11 | |
| SCHEMBL24580648 | 0.75 | ALDH1A1 (0.42) | SMN1; SMN2POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107219-A1 | AZABENZIMIDAZOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-04-20 | — | — | US | disclosed |
| US-9567330-B2 | Azabenzimidazole derivative having AMPK-activating activity | SHIONOGI & CO., LTD. (JP) | 2017-02-14 | — | — | US | disclosed |
| US-9567330-B2 | Azabenzimidazole derivative having AMPK-activating activity | SHIONOGI & CO., LTD. (JP) | 2017-02-14 | — | — | US | disclosed |
| US-20140194420-A1 | AZABENZIMIDAZOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107219-A1 | AZABENZIMIDAZOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | PRKAB1, PRKAB2, PRKAG1 | USP2 3865/4885SMN1; SMN2 4254/4885CYP4F2 2660/4885 |
| US-20140194420-A1 | AZABENZIMIDAZOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | PRKAB1, PRKAB2, PRKAG1 | USP2 3865/4885SMN1; SMN2 4254/4885CYP4F2 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.